UK alarm bells are ringing as a biotech cuts a few trial sites, fretting over Brexit’s impact on drug development
A very low-profile transatlantic biotech has found a place in the spotlight for the first time with its decision to cut UK trial sites out of an upcoming heart drug study — evidently due to uncertainty about drug development in a post-Brexit world.
The BBC reported the move by a company called Recardio — with offices in Austria and San Francisco — which will likely stoke new fears that the UK’s impending departure from the EU will severely disrupt the country’s biopharma industry. So far, that’s been playing out with warnings over a possible interruption in drug supplies unless the UK can hammer out an exit deal that muffles any fallout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.